iNtRON Biotechnology
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
iNtRON Biotechnology develops drugs and diagnostic kits that target bacterial infections and immune diseases, using viruses called bacteriophages, which naturally attack and destroy bacteria, as the core of its technology.
Its two main drug-development platforms, itLysin and IMPA, engineer bacteriophages and their derived enzymes to create treatments aimed at antibiotic-resistant bacteria and immune conditions. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company runs a separate diagnostics division that makes PCR-based test kits for infectious diseases in humans and animals, which it describes as the revenue-generating arm that supports its longer-term drug pipeline.
Summary is AI-generated and may contain errors · figures from DART filings
iNtRON Biotechnology in five facts
What does iNtRON Biotechnology do?
iNtRON Biotechnology develops drugs and diagnostic kits that target bacterial infections and immune diseases, using viruses called bacteriophages, which naturally attack and destroy bacteria, as the core of its technology.
Where is iNtRON Biotechnology listed and in which sector?
iNtRON Biotechnology (Korean name: 인트론바이오) trades under KRX code 048530 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is iNtRON Biotechnology?
Its market capitalisation was US$68.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were iNtRON Biotechnology's latest annual revenue and operating profit?
For fiscal year 2025, iNtRON Biotechnology reported revenue of US$4.3M, an operating loss of US$6M and a net loss of US$6.8M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 10.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Other management matter (voluntary)Sep 2
- Material event report (convertible bonds)
iNtRON Biotechnology disclosed convertible bonds to raise US$1.94M, about 3.4% of its market value.
Capital raise · Jun 30 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
iNtRON Biotechnology reported consolidated results for FY2025: revenue of US$3.97M (−10.56% year on year), an operating loss of US$5.47M and a net loss of US$6.41M.
Earnings · Feb 12